The article, titled “RNA therapeutics for epilepsy: An emerging modality for drug discovery,” outlines the limitations of current antiseizure medications and highlights RNA-based therapies as a promising new approach to address drug resistance and achieve disease modification in epilepsy.
The review presents strategies for targeting both noncoding RNAs—such as microRNAs, long noncoding RNAs, and circular RNAs—and messenger RNAs, depending on the patient population. Noncoding RNA targeting shows particular promise in sporadic, drug-resistant epilepsy, while mRNA-targeted approaches may offer new possibilities in monogenic childhood epilepsies.
This work contributes to the growing interest in RNA-based drug development for neurological diseases and supports Neumirna’s ongoing efforts to pioneer novel RNA therapies in epilepsy.
Read the full article in Epilepsia.
